Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The purpose of the current study is to evaluate whether there is immune interference when MenABCWY [consisting of MenACWY lyophilized component and rMenB+OMV NZ (Bexsero) liquid component] is administered to healthy adolescents and adults following a 2‐dose vaccination schedule with MenABCWY administered 2 months apart.
Epistemonikos ID: 6cced39307a56cf8f0bf70baf4a936a10235a341
First added on: May 21, 2024